

Jing-Quan Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9255159/publications.pdf>

Version: 2024-02-01

62
papers

1,789
citations

304743

22
h-index

289244

40
g-index

63
all docs

63
docs citations

63
times ranked

1710
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018, 41, 1-25. | 14.4 | 420 |
| 2 | Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance. <i>Drug Resistance Updates</i> , 2021, 54, 100743. | 14.4 | 107 |
| 3 | Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. <i>Cancer Letters</i> , 2019, 440-441, 82-93. | 7.2 | 83 |
| 4 | Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. <i>Drug Discovery Today</i> , 2021, 26, 1284-1292. | 6.4 | 65 |
| 5 | ATP-binding cassette (ABC) transporters in cancer: A review of recent updates. <i>Journal of Evidence-Based Medicine</i> , 2021, 14, 232-256. | 1.8 | 57 |
| 6 | Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5988-6001. | 6.4 | 53 |
| 7 | Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. <i>Biochemical Pharmacology</i> , 2019, 166, 120-127. | 4.4 | 52 |
| 8 | Olmudinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1097. | 3.5 | 47 |
| 9 | Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Biochemical Pharmacology</i> , 2018, 158, 274-285. | 4.4 | 47 |
| 10 | Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. <i>Molecules</i> , 2019, 24, 4383. | 3.8 | 46 |
| 11 | VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters. <i>Frontiers in Pharmacology</i> , 2018, 9, 1236. | 3.5 | 41 |
| 12 | FRP stay-in-place form and shear key connection for FRP-concrete hybrid beams/decks. <i>Composite Structures</i> , 2018, 192, 489-499. | 5.8 | 40 |
| 13 | Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. <i>Cancers</i> , 2020, 12, 466. | 3.7 | 37 |
| 14 | Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Cancers</i> , 2020, 12, 186. | 3.7 | 33 |
| 15 | Bolted Shear Connection of FRP-Concrete Hybrid Beams. <i>Journal of Composites for Construction</i> , 2018, 22, . | 3.2 | 31 |
| 16 | Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible. <i>Future Medicinal Chemistry</i> , 2019, 11, 323-336. | 2.3 | 31 |
| 17 | Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 955. | 2.8 | 31 |
| 18 | Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 671788. | 2.7 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study. <i>Frontiers in Oncology</i> , 2019, 9, 514. | 2.8 | 29 |
| 20 | Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 849-862. | 5.5 | 28 |
| 21 | Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro. <i>Frontiers in Oncology</i> , 2020, 10, 700. | 2.8 | 25 |
| 22 | Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1387. | 4.1 | 25 |
| 23 | Modulating the function of ABCB1: <i>in vitro</i> and <i>in vivo</i> characterization of sitravatinib, a tyrosine kinase inhibitor. <i>Cancer Communications</i> , 2020, 40, 285-300. | 9.2 | 24 |
| 24 | Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells. <i>Cancer Science</i> , 2020, 111, 2872-2882. | 3.9 | 24 |
| 25 | Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 1208. | 3.5 | 23 |
| 26 | Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance. <i>European Journal of Pharmacology</i> , 2019, 863, 172611. | 3.5 | 22 |
| 27 | The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide. <i>Cancers</i> , 2020, 12, 1963. | 3.7 | 21 |
| 28 | Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. <i>Biochemical Pharmacology</i> , 2020, 175, 113848. | 4.4 | 21 |
| 29 | Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4095. | 4.1 | 19 |
| 30 | Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells. <i>Cancers</i> , 2020, 12, 3249. | 3.7 | 19 |
| 31 | Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction. <i>Protein and Cell</i> , 2021, 12, 586-591. | 11.0 | 18 |
| 32 | Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 601400. | 3.7 | 18 |
| 33 | M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 674. | 2.8 | 18 |
| 34 | Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 228. | 2.8 | 15 |
| 35 | Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 615824. | 3.5 | 14 |
| 36 | Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 865. | 3.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Dynamic characteristics analysis of partial-interaction composite continuous beams. <i>Steel and Composite Structures</i> , 2016, 21, 195-216. | 1.3 | 13 |
| 38 | Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2021, 136, 111223. | 5.6 | 12 |
| 39 | NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1219. | 2.8 | 11 |
| 40 | Overexpression of ABCC1 Confers Drug Resistance to Betulin. <i>Frontiers in Oncology</i> , 2021, 11, 640656. | 2.8 | 11 |
| 41 | The role of androgen therapy in prostate cancer: from testosterone replacement therapy to bipolar androgen therapy. <i>Drug Discovery Today</i> , 2021, 26, 1293-1301. | 6.4 | 11 |
| 42 | The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2463. | 4.1 | 10 |
| 43 | Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 607275. | 3.7 | 9 |
| 44 | Natural Product as Substrates of ABC Transporters: A Review. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021, 16, 222-238. | 1.6 | 9 |
| 45 | OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. <i>Frontiers in Pharmacology</i> , 2021, 12, 620874. | 3.5 | 8 |
| 46 | Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697927. | 3.7 | 8 |
| 47 | Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. <i>Experimental Cell Research</i> , 2021, 405, 112728. | 2.6 | 8 |
| 48 | Insights on the structure–function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. <i>MedComm</i> , 2021, 2, 221-235. | 7.2 | 7 |
| 49 | MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2609-2618. | 12.0 | 7 |
| 50 | Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression. <i>Frontiers in Oncology</i> , 2021, 11, 731260. | 2.8 | 6 |
| 51 | PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study. <i>Molecular Cancer</i> , 2022, 21, 40. | 19.2 | 5 |
| 52 | Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells. <i>Frontiers in Pharmacology</i> , 2022, 13, 843829. | 3.5 | 5 |
| 53 | VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. <i>Cancers</i> , 2021, 13, 4675. | 3.7 | 4 |
| 54 | The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. <i>International Journal of Biological Sciences</i> , 2021, 17, 2652-2665. | 6.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Therapeutic implication of carbon monoxide in drug resistant cancers. <i>Biochemical Pharmacology</i> , 2022, 201, 115061. | 4.4 | 4 |
| 56 | VSV-G Viral Envelope Glycoprotein Prepared from <i>Pichia pastoris</i> Enhances Transfection of DNA into Animal Cells. <i>Journal of Microbiology and Biotechnology</i> , 2017, 27, 1098-1105. | 2.1 | 3 |
| 57 | Abstract 2983: A synthetic derivative of 1,2,3-triazole-pyrimidine hybrid reverses multidrug resistance mediated by MRP7. , 2020, , . | | 2 |
| 58 | Abstract 3796: Selonsertib, an ASK1 inhibitor, antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. <i>Cancer Research</i> , 2019, 79, 3796-3796. | 0.9 | 1 |
| 59 | Abstract 3006: Anticancer and multidrug resistance-reversing activities of novel antimicrobial peptides. , 2020, , . | | 1 |
| 60 | Abstract 3010: VKNG 1 reverses multidrug resistance by inhibiting ABCG2 mediated drug transport in vitro and in vivo. , 2020, , . | | 1 |
| 61 | Paclitaxel and chemoresistance. , 2022, , 251-267. | | 1 |
| 62 | Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2021, 16, 44-53. | 1.6 | 0 |